master class regulatory affairs
TRANSCRIPT
Master class Regulatory Affairs
22-April-2021
Alex Zwiers
Intro to Zwiers
2
Founded in 2011 – now 30 employees - >40 clients
Pharma – medical devices - biocides – cosmetics- borderline products
Pharma, regulatory affairs – from patent to submission to end of life cycle
Medical devices - from ISO 13485 to complete technical file
Other activities
3
PublishingSubmissions of electronic dossiers (e-IND, e-CTDs)
(pharmaco)vigilanceQPPV/ PV systems/ audits
Training: Several training modules
Spin-off regulatory science
4
A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines Marjolein Garsen, Maaike Steenhof & Alex Zwiers
Therapeutic Innovation & Regulatory Science (2021)
Implementation of Quality by Design (QbD) Principles in Regulatory Dossiers of Medicinal Products in the European Union (EU) Between 2014 and 2019. Ter Horst JP1, Turimella SL1, Metsers F1, Zwiers A1 Therapeutic Innovation & Regulatory Science, 13 Jan 2021, 55(3):583-590
What can you expect?
5
Medicinal products: to merge the basic concepts with typical examples and supplemented by our regulatory science projectsIn order to prevent
What can you not expect
6
Today no information on medical devices, becauseHowever, should you have questions: contact us at: [email protected]
Agenda:
7
3 important questions Two examples
Important questions
8
When we start to work on a project we want to know:
What is your product?What is the legal basis?Which regulatory procedure?
Why should you also know the answers to these questions very early?
Question 1: What is your product?
9
• Legal definitions : Medicinal product vs medical device vs cosmetic/ food or borderline / combination product
• Claims & dosage Medicinal product vs food
Medicinal substanceAny substance or combination of substancespresented as having properties for treating orpreventing diseases in human beings;orAny substance or combination of substanceswhich may be used in or administered tohuman beings either with a view to restoring,correcting or modifying physiologicalfunctions by exerting a pharmacological,immunological or metabolic action, or tomaking a medicinal diagnosis.
MPD 2001/83/EC
Medicinal substance
• Pharmacological,• Immunological or• metabolic action
Question 1: What is your product?
10
• Legal classificationsSome products are classified per law
• Pharmaceutical classificationATC – which group?
How well do you know your own product?
11
Product for neuropathic pain: what is the indication?post-herpetic neuralgia painful diabetic neuropathyBack painTreatment of neuropathic painTreatment and prevention of neuropathic pain?
How well do you know your own product
12
Important tool to know your product
13
Very useful documentNot mandatory, can be included in the pre-INDOther formats are OKForces you to think about the end (labeling)
What if you still do not know it?
14
Seek scientific advice:EMA – interesting with SME statusIndividual health authorities: CBG, MPA, BfArM, MHRA E.g. CBG – ‘advies op maat’ (repurposing)Take care that you have generated essential data!
Our regulatory science: Garsen et al., 2021
Scientific advice links
15
CBG:https://www.cbg-meb.nl/onderwerpen/hv-wetenschappelijk-en-regulatoir-adviesEMA:https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance
The application form for scientific advice of the CBG
16
What is the legal basis? (which article applies?)
17
Art. 8.3 Stand-alone / full dossier Art. 10.1 Generic Art. 10.3 Hybrid Art. 10.4 Similar biological Art. 10 (a) Well-established use Art. 10 (b) Fixed combination
What are the regulatory procedures?
18
Why is it important to know which regulatory procedure you could or should follow?
FeesTimelinesStrategyDifferent parties to interact
Centralised Procedure - CP
19
CP
Single submission to EMA
Approval by European Commision
Valid in the entire EU territory
Optional: New Active SubstanceMandatory: Biotech products, ATMPs,
certain therapeutics classes (oncology), and orphan products
210 days (+ clockstops)All EU Member
StatesAccelerated to 150 days
Regulatory toolbox
20
Early market access
less data
fastermore input
Conditional approvalExceptional circumstancesAccelerated assessmentPRIME
Regulatory toolboxConditional approval: Medicines that fulfil an unmet medical need;The benefit of immediate availability for patients is greater than the risk of less comprehensive data than normally required;The authorization is valid for1 year and will be renewed every year.
Exceptional circumstances: The company is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the condition to be treated is rare or because collection of full information is not possible or is unethical
21
Regulatory toolboxAccelerated assessment:Applications may be eligible for accelerated assessment if the CHMP decides the product is of major interest for public health and therapeutic innovation.
PRIME (PRIority MEdicnes):This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.The scheme focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. These medicines are considered priority medicines by EMA.
22
COVID-19 vaccines, regulatory tools
23
Scientific advice (free)COVID-19 pandemic task forceAdditional resourcesQuicker manufacturing site approval Rolling reviewAccelerated assessment (<150d)Conditional approvalLarge scale safety monitoring
Source: EMA website: covid-19-vaccines-development-evaluation-approval-monitoring
CHMP opinion between January 2010 and December 2019 , n= 96
EMA orphan designation/ expedited program %
Accelerated assessment (AA) 14 (15%)
Conditional marketing authorization (CMA) 23 (24%)
Orphan designation (OD) 40 (42%)
Priority medicine (PRIME) 3 (3%)
24
CHMP opinion between January 2010 and December 2019 , n= 96
25
EMA orphan designation/ expedited program %
AA & CMA 3 (3%)
AA & PRIME 0 (0%)
CMA & PRIME 1 (1%)
Expedited program (AA, CMA & PRIME) 34 (35%)
No expedited program (AA, CMA & PRIME) 62 (65%)
OD/ no expedited program (AA, CMA & PRIME) 27 (28%)
No OD/ no expedited program (AA, CMA & PRIME) 38 (40%)
Figures for Centralised procedure
26
Source: https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines/medicine-evaluation-figures#annual-medicines-highlights-(2015-2020)-section
Mutual Recognition Procedure – MRP Decentralised Procedure - DCP
27
One or more EU Member States
MRP
Sequential approach: national procedure →Reference MS followed by Concerned MS
Where the medicinal product has already received in a MS a MA at the time of
application
90 days + 30 days (national phase)
DCP
Parallel submission to RMS and CMS
210 days + 30 days (national phase)
MRP or DCP - Statistics of finalised MRP/DCP
MRP188 Generic42 Hybrid
DCP744 Generic133 Hybrid
How can this old drug be approved via the CP?
29
Via the CP = ??Nationally approved = generic
We talked about:
30
Accelerated approvalConditional approvalRepurposing(bio) genericsHybridsPRIME
TPPOrphan drugsCP/ DCP/ MRP/nationalLegal basisScientific adviceExceptional circumstances
Let’s not forget the content!
31
Common Technical Document:An agreed-upon common format for the “modular” presentation of summaries, reports and dataIncorporates relevant ICH guidelinesElectronic CTD
Two examples:
32
Old drug new formulationOncology product
Oncology product
Impact of regulatory status on time to approvalEffect of company size on outcome
33
Impact of orphan / conditional or accelerated review on approval?
34
Effect of company size on succes?
35
Old drug with new formulation
36
Which legal basis: hybrid or full application (based on own studies and literature)?Do we need to do a clinical study ? Maybe one only?Toxicology studies for a product of more than 30 years old?
Which legal basis?
37
Has impact on:Data requirementPediatric studiesData exclusivityYes/no reference required....
Legal basis
Article 8(3) Full(-mixed) application
Article 10(1) Generic application
Article 10(3) Hybrid application
Article 10(4) Biosimilar application
Article 10a Well-established use application
Article 10b Fixed combination application
Article 10c Informed consent application
Which legal basis?
38
Full mixed application: combination of your own studies + literature. Hybrid application – you refer to another product, but no need to be bioequivalent (is not a generic). Strategy is to bridge and do studies and try to cover the difference.
Do we need to do a clinical study ?
39
Regulatory science project
40
40 MAAs for repurposed drugs using article 8(3) full-mixed dossier• 28 new formulation • 7 new indication • 5 both new formulation and new indication
Period covered: 2000-2017
New formulation, clinical (33 MAA)
41
% applicants performing own clinical studies
# own studies # pivotal studies
Pharmacokinetics 79% 1-15 NA
Pharmacodynamics 21% 1-8 NA
Safety/efficacy 100% 1-7 (average 1-3) 1-2
93% of the applicants used data from the literatureAll applicants performed at least one clinical study
Toxicology studies needed?
42
Toxicology studies needed?
43
Required Normally not
necessary
Pharmacology
X
Pharmacokinetics
X
Single/repeat dose toxicity (including local tolerance)
X
Reproductive toxicity X1
Genotoxicity X
Carcinogenicity
X
New formulation, preclinical (33 MAA)
44
All applicants used data from the literature
91% of applicants performed at least one preclinical study
% applicants performing own preclinical studies
Guideline non-clinical studies full-mixed MAA
Pharmacology 42% Normally not necessary
Pharmacokinetics 53% Normally not necessary
Single/repeat dose toxicity (including local tolerance)
82% Normally not necessary
Reproductive toxicity 23% Required
Genotoxicity 39% Required
Carcinogenicity 10% Normally not necessary
Links to guidelines
45
ICH E1: https://database.ich.org/sites/default/files/E1_Guideline.pdf
ICH S6: https://www.ema.europa.eu/en/ich-s6-r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals
ICH S9: https://www.ema.europa.eu/en/ich-s9-non-clinical-evaluation-anticancer-pharmaceuticalshttps://www.ema.europa.eu/en/non-clinical-documentation-mixed-marketing-authorisation-applications
Publication Garsen et al: A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines: https://pubmed.ncbi.nlm.nih.gov/33543409/
Thank you for your attention!
www.az-regulatory.com
46